Pancreatic Cancer Trial, Recruiting NCT06139042 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06139042
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Cancer Group:

  • You are between 40 and 75 years old on the day you sign up for the study
  • You are able to read and sign a consent form agreeing to take part
  • You have been diagnosed with liver, bile duct, or pancreatic cancer, confirmed by a medical test
  • You have not had any cancer treatments (such as surgery, chemotherapy, or radiation) before the blood sample is taken

Benign Disease Group (non-cancerous conditions):

  • You are between 40 and 75 years old on the day you sign up for the study
  • You are able to read and sign a consent form agreeing to take part
  • You have been diagnosed with a non-cancerous condition of the liver, bile duct, or pancreas
  • You have not had a major treatment for your condition before the blood sample is taken

Healthy Group:

  • You are able to read and sign a consent form agreeing to take part
  • You are able to provide a suitable blood sample for testing
  • You have not had any symptoms related to cancer in the 30 days before screening
  • If you have had cancer in the past, your treatment finished more than 3 years ago and the cancer has not come back

Who may not be able to join:

Cancer and Benign Disease Groups:

  • You are currently pregnant or breastfeeding
  • You have had an organ transplant, or a bone marrow or stem cell transplant from another person
  • You received a blood transfusion in the 7 days before your blood sample is taken
  • You have received any cancer-related treatment in the 30 days before your blood sample, for a condition other than cancer
  • You have been diagnosed with any other type of cancer or multiple tumours (cancer group), or any cancer or pre-cancerous condition (benign group)

Healthy Group:

  • Your blood sample is not sufficient or suitable for testing
  • You are currently pregnant or breastfeeding
  • You have had an organ transplant, or a bone marrow or stem cell transplant from another person
  • You received a blood transfusion in the 30 days before your blood sample is taken
  • You have taken antibiotics or other infection-fighting medication in the 14 days before your blood sample is taken
  • You have received or are currently receiving cancer treatment within the last 3 years
  • You have an autoimmune disease or another serious long-term health condition (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Weilin Wang, Phd, Second Affiliated Hospital, School of Medicine, Zhejiang University

Phone: +8657187783820

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 November 2023
Est. completion
30 June 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The sensitivity and specificity of the cfDNA methylation model in detection of liver, biliary tract and pancreatic cancers.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov